Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
98,294,118
-
Total 13F shares
-
62,590,275
-
Share change
-
+2,642,192
-
Total reported value
-
$533,041,807
-
Put/Call ratio
-
6.1%
-
Price per share
-
$8.51
-
Number of holders
-
112
-
Value change
-
+$21,909,612
-
Number of buys
-
65
-
Number of sells
-
45
Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) as of Q2 2024
As of 30 Jun 2024,
ARS Pharmaceuticals, Inc. - Common Stock (SPRY) was held by
112 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
62,590,275 shares.
The largest 10 holders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, BlackRock Inc., SR One Capital Management, LP, VANGUARD GROUP INC, FRANKLIN RESOURCES INC, K2 PRINCIPAL FUND, L.P., Nextech Invest Ltd., and STATE STREET CORP.
This page lists
112
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.